Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MabThera Plus Chemotherapy vs Chemotherapy Alone in Indolent NHL and MCL
NCT00269113Phase 3Completed
- Sponsor
- Roche
- Start
- Sep 1998
- Primary completion
- Apr 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab in Indolent Non-Hodgkin Lymphoma (INHL) and mantle cell lymphoma (MCL) (2 arms), sponsored by Roche. Primary endpoint: Percentage of Participants Achieving CR or PR at the End of Therapy at 24 weeks. Started Sep 1998; status: completed.
02
Drugs
rituximab
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00269113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00269113.